The U.S. Department of Justice is aggressively targeting telehealth companies that use sham physician relationships and medically unnecessary orders to defraud Medicare, with recent convictions revealing schemes worth tens of millions of dollars. Between late February and early March 2026, four individuals were sentenced for orchestrating elaborate Medicare fraud schemes that exploited telehealth platforms to submit false claims for orthotic braces and other durable medical equipment (DME) that patients never needed or requested .

What Are These Telehealth Fraud Schemes Actually Doing?

The cases prosecuted by the DOJ reveal a troubling pattern: telehealth companies partner with marketing firms and overseas call centers to identify Medicare beneficiaries, then use physicians with no actual treating relationship to sign prescriptions for expensive orthotic braces. The braces are shipped to patients who neither requested them nor had any clinical need for them, yet Medicare foots the bill. When one scheme gets exposed, the perpetrators simply open a successor company under a third party's name while maintaining actual control .

The scale of these operations is staggering. Reinaldo Wilson, owner of two New Jersey-based telemedicine companies, orchestrated a scheme that generated over $56 million in fraudulent Medicare claims by paying illegal kickbacks to providers to sign unnecessary brace orders. Similarly, Dr. Scott Taggart Roethle, a Kansas anesthesiologist, signed fraudulent DME prescriptions without examining patients, resulting in at least $8 million in Medicare losses. In another case, Georgia chiropractor Teflyon Cameron and her co-conspirators caused over $14.9 million in Medicare losses through sham contractual arrangements designed to disguise kickback payments .

How Is the Government Fighting Back Against Healthcare Fraud?

• Anti-Kickback Statute Enforcement: The DOJ is reinforcing scrutiny under the Anti-Kickback Statute, which prohibits payments designed to induce referrals or orders for healthcare services. Multiple recent convictions specifically targeted illegal kickback schemes disguised as legitimate business arrangements.
• False Claims Act Prosecution: Federal prosecutors are using the False Claims Act to hold companies accountable for submitting fraudulent claims to Medicare, with sentences including prison time and substantial restitution orders.
• AI-Powered Fraud Detection: The administration's Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative is expanding the use of artificial intelligence to detect fraud patterns across Medicare claims, signaling a technological shift in enforcement capabilities .

Beyond criminal prosecution, the Centers for Medicare and Medicaid Services (CMS) is modernizing how it identifies suspicious activity. The CRUSH initiative represents a significant pivot toward using AI algorithms to flag potentially fraudulent claims before they're paid, rather than relying solely on post-hoc investigations. This proactive approach could prevent billions in losses, though it also raises questions about how AI systems distinguish between legitimate edge cases and intentional fraud .

Why Is CMS Now Asking for AI Tools to Help Medicare Beneficiaries?

In a parallel development, CMS issued a Request for Information (RFI) on February 24, 2026, seeking artificial intelligence tools that could help Medicare beneficiaries navigate plan selection. The agency noted that approximately 70 million Medicare beneficiaries currently evaluate coverage options through Medicare.gov, the Medicare Plan Finder, and the Medicare Call Center, but these tools may be difficult to navigate or subject to extended wait times .

CMS is specifically interested in AI solutions that can provide personalized plan recommendations, real-time conversational support, predictive analytics, accessible decision-support tools, and call center automation. Importantly, the agency imposed a critical restriction: respondents must not be affiliated with or owned by insurance carriers, health plans, or any entity with a financial incentive to steer beneficiaries toward specific plans. This safeguard suggests CMS learned from the telehealth fraud cases that financial conflicts of interest can corrupt the entire system. Responses to the RFI are due by March 31, 2026, with formal solicitations anticipated to follow .

The contrast between these two initiatives is striking. On one hand, the government is prosecuting fraudsters who exploit telehealth and DME ordering systems. On the other hand, it's actively seeking AI tools to improve beneficiary experiences and reduce administrative burden. This dual approach suggests policymakers recognize that technology itself isn't the problem; rather, it's how technology is deployed and governed that determines whether it protects or exploits vulnerable populations.

What Does This Mean for Healthcare's AI Future?

The recent enforcement actions and CMS initiatives reflect a broader regulatory shift toward what experts call "clinical AI" and risk-based oversight. Federal agencies are accelerating digital health adoption while simultaneously tightening controls on how that technology can be misused. The Senate Health Committee has recommended streamlined FDA regulation of AI-driven healthcare innovations, signaling that policymakers want to move faster on beneficial applications while maintaining guardrails against fraud and abuse .

States are also experimenting with AI-enabled healthcare programs. Utah launched an AI-enabled prescription renewal program, suggesting that when properly designed and overseen, AI can genuinely improve healthcare delivery. The key difference between these legitimate applications and the fraudulent schemes is transparency, oversight, and alignment with patient interests rather than profit extraction .

For healthcare providers, insurers, and technology companies, the message is clear: the era of unregulated telehealth and AI-driven healthcare is ending. The DOJ's aggressive prosecution of telehealth fraud schemes, combined with CMS's push for AI tools that prioritize beneficiary interests, signals that regulators will distinguish between innovation that serves patients and schemes that exploit them. Companies that build AI systems with proper safeguards, transparent decision-making, and genuine clinical benefit will thrive. Those that use technology to obscure fraud will face federal prosecution.

" }